Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

Samankaltaisia teoksia

• Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
  Tekijä: Raedler, Lisa A.
  Julkaistu: (2015)
• Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
  Tekijä: Raedler, Lisa A.
  Julkaistu: (2015)
• Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
  Tekijä: Raedler, Lisa A.
  Julkaistu: (2015)
• Pembrolizumab (Keytruda)
  Tekijä: Kwok, Gerry, et al.
  Julkaistu: (2016)
• Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
  Tekijä: Raedler, Lisa A.
  Julkaistu: (2016)